Detalhe da pesquisa
1.
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.
J Antimicrob Chemother
; 76(12): 3286-3295, 2021 11 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34450619